1.Research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma
Jiang CHANG ; Yichao GU ; Xiangcheng LI
Chinese Journal of Digestive Surgery 2021;20(2):250-254
Cholangiocarcinoma is a rarely malignant tumor with poor overall prognosis. Radical surgery is the only strategy to improve the long-term survival of patients with cholangio-carcinoma of early-stage. For most patients with advanced cholangiocarcinoma, systematic treatment has become the main strategy. But the available first-line drugs for the treatment of cholangiocarcinoma are limited and the curative effect is limited. In recent years, immunotherapy strategies such as immune checkpoint inhibitors have achieved encouraging results in a variety of solid tumors by using the host immune system to carry out effective anti-tumor responses. The authors summarize the research advances of immune checkpoint inhibitors in the treatment of cholangiocarcinoma.
2.Emergency use authorization for Ebola virus detection by FDA-approved techniques
Yajun GU ; Tiantian SHE ; Hongwei FU ; Wei QIN ; Yichao WANG ; Yunde LIU
Chinese Journal of Experimental and Clinical Virology 2016;30(5):496-499
Ebola virus (EBOV) is an aggressive pathogen that causes a highly hemorrhagic fever syndrome in humans and other mammalian species.Early detection and proper treatment is the best defense against EBOV because of high mortality rate (70%-90%).Currently,there are eleven FDA approved Ebola tests,kits,or assays for emergency use,which can be divided into two main categories:rRT-PCR and viral antigen methods.In BSL 4 lab,rRT-PCR is the most sensitive technique to detect nucleic acid of Ebola virus,including Ebola Zaire (EZ1) rRT-PCR (TaqMan) Assay,Ebola Virus NP and VP40 Real-time RTPCR Assay,FilmArray NGDS BT-E and Biothreat-E test,RealStar Ebolavirus RT-PCR kit,LightMix Ebola Zaire rRT-PCR test,and Xpert Ebola Assay.Antigen-based technology (ReEBOV Antigen Rapid Test,and OraQuick Ebola Rapid Antigen Test) provides rapid Ebola antigen test without relying on special PCR equipment.How to develop,manufacture,and market point-of-care and field testing will be the next major challenge for EBOV on various samples.
3.Evaluation of clinical application of automatic coagulation detection assembly line in high-throughput specimen detection
Hui WU ; Lin SUN ; Meixiu GU ; Yichao GUO ; Chong WANG ; Beili WANG ; Baishen PAN ; Wei GUO
International Journal of Laboratory Medicine 2024;45(12):1416-1418,1424
Objective To evaluate the clinical application of automatic coagulation detection assembly line in high-throughput specimen detection.Methods The relevant information of sodium citrate anticoagulation samples in Zhongshan Hospital Affiliated to Fudan University from June to August 2021 was collected,inclu-ding sample collection time,receiving time,instrument sucking time,test completion time,and whether it pas-sed autoverification or not.The sample pretreatment time,testing time and turnaround time(TAT)of the au-tomatic coagulation detection assembly line were compared before and after installation,and the detection speed of the automatic coagulation detection assembly line was evaluated.Results The automatic coagulation detection line was expected to detect 650-900 samples per hour.The increase in the number of turbidimetric tests would slow down the detection speed of the instrument.Automatic coagulation detection assembly line test specimen to clinic and ward of pretreatment time and testing time were shorter than single detection,the differences were statistically significant(P<0.05).The automatic coagulation detection assembly line could shorten TAT(P<0.05).After the application of automatic coagulation detection assembly line,the autoveri-fication rate was 25.6%.Conclusion The automatic coagulation detection assembly line is suitable for high-throughput specimen detection in laboratory.Compared with stand-alone coagulation detection,the automatic coagulation detection assembly line could shorten TAT and testing time,and help to reduce the work pressure of laboratory personnel.
4.Mowat-Wilson syndrome with Hirschsprung′s disease and vaginal atresia: case report and literature review
Shuangshuang LI ; Yong ZHAO ; Junmin LIAO ; Yanan ZHANG ; Yichao GU ; Kaiyun HUA ; Dingding WANG ; Jinshi HUANG
Chinese Journal of Applied Clinical Pediatrics 2022;37(23):1822-1824
Clinical phenotypes and gene characteristics of a patient diagnosed with Mowat-Wilson syndrome (MWS) with Hirschsprung′s disease (HSCR) and vaginal atresia in the Department of Neonatal Surgery, Beijing Children′s Hospital, Capital Medical University in March 2021 were analyzed retrospectively.The eight-month-old girl was admitted to the hospital with symptoms of constipation for nine days and abdominal distension for two days.Lower digestive tract radiography and rectal mucosa biopsy results suggested HSCR.The child also had specific facial features and motor development delay.Whole exome test showed a de novo heterozygous mutation, ZEB2 gene c. 2761C>T (p.R921*). After laparoscopic-assisted Soave procedure, the child had normal bowel movements, and no surgery-related compli-cations occurred during the follow-up period.The child′s motor development improved after rehabilitation treatment.According to literature review, 2 female cases show similar clinical manifestations to this girl, but the genotypes were different.This patient expands the clinical phenotype of ZEB2 gene pathogenicity.